Articles
10 June 2009
Vol. 2 No. 13: It’s time to take care of T-Cell Lymphomas Bologna, Italy, 22-24 October 2006
https://doi.org/10.4081/hmr.v2i13.482
0
0
0
0
Smart Citations
0
0
0
0
Citing PublicationsSupportingMentioningContrasting
View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: clinical activity and molecular markers

Authors

RL Piekarz
support@pagepress.org
R Frye
M Turner
J Turner
S Allen
MH Kirschbaum
J Zain
M Prince
Histone deacetylase inhibitors induce changes in gene expression that lead to cellular differentiation and reversal of the transformed phenotype. In addition, acetylation of centromeric chromatin and non-histone proteins also likely plays a role in cytotoxicity due to romi depsin. Interest in clinical development of these agents has been spurred by the responses observed in patients with peripheral or cutaneous T-cell lymphoma to romidepsin, previously FK228 or depsipeptide.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Phase II trial of romidepsin (FK228 or depsipeptide) in peripheral T-cell lymphoma: clinical activity and molecular markers. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(13). https://doi.org/10.4081/hmr.v2i13.482